Literature DB >> 9741372

Totally implantable venous access devices in children with cystic fibrosis: incidence and type of complications.

J Deerojanawong1, S M Sawyer, A M Fink, K B Stokes, C F Robertson.   

Abstract

BACKGROUND: Totally implantable vascular access devices (TIVADs) are accepted as a safe and effective method of facilitating long term intravenous therapy. We report our experience of the use of these devices in children with cystic fibrosis with a particular focus on the incidence and type of complications.
METHODS: The medical records of patients with cystic fibrosis who underwent placement of a TIVAD at the Royal Children's Hospital, Melbourne, Australia from January 1987 to October 1996 were reviewed. Venous ultrasonography with Doppler was performed in surviving patients with a TIVAD in situ from November 1996 to April 1997 to detect occult thrombotic complications.
RESULTS: A total of 57 TIVADs were implanted in 44 children with a median functional duration of 700 days (range 27-3347 days). Twenty one children had devices inserted without complications. Forty eight complications (30 mechanical, 18 infectious) occurred in 36 devices in 23 children during a total functional duration of 53,057 catheter days. Mechanical complications occurred in 53% of devices (one per 1712 catheter days). Symptomatic venous thrombosis occurred five times in four patients (9%). Infectious complications occurred in 32% (one per 2948 catheter days) while sepsis occurred in five devices (9%). Doppler ultrasonography detected unsuspected thrombosis in two of 10 patients examined.
CONCLUSIONS: While TIVADs provided effective long term intravenous access, septic and thrombotic complications caused significant morbidity in this population. Careful patient selection, adherence to aseptic technique for access and blood sampling, and periodic ultrasonography with Doppler to detect early thrombosis may help reduce these risks.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741372      PMCID: PMC1745200          DOI: 10.1136/thx.53.4.285

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  21 in total

1.  Totally implantable vascular access devices in cystic fibrosis: a four-year experience with fifty-eight patients.

Authors:  J B Morris; M E Occhionero; M W Gauderer; R C Stern; C F Doershuk
Journal:  J Pediatr       Date:  1990-07       Impact factor: 4.406

2.  Totally implantable venous access devices in adult patients with cystic fibrosis.

Authors:  B Yung; I A Campbell; J S Elborn; J S Harvey; D J Shale
Journal:  Respir Med       Date:  1996-07       Impact factor: 3.415

3.  Use of a totally implantable system for venous access in cystic fibrosis.

Authors:  R J Stead; T I Davidson; F R Duncan; M E Hodson; J C Batten
Journal:  Thorax       Date:  1987-02       Impact factor: 9.139

4.  Complications of TPN catheter-induced vena caval thrombosis in children less than one year of age.

Authors:  D L Mollitt; E S Golladay
Journal:  J Pediatr Surg       Date:  1983-08       Impact factor: 2.545

5.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.

Authors:  M M Bern; J J Lokich; S R Wallach; A Bothe; P N Benotti; C F Arkin; F A Greco; M Huberman; C Moore
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

6.  Bacteraemia and fungaemia in adults with cystic fibrosis.

Authors:  J V Fahy; M T Keoghan; E J Crummy; M X FitzGerald
Journal:  J Infect       Date:  1991-05       Impact factor: 6.072

7.  Safety and efficacy of thrombolytic therapy for superior vena cava syndrome.

Authors:  B H Gray; J W Olin; R A Graor; J R Young; J R Bartholomew; W F Ruschhaupt
Journal:  Chest       Date:  1991-01       Impact factor: 9.410

8.  Thrombus associated with central venous catheters in infants and children.

Authors:  P Ross; R Ehrenkranz; C S Kleinman; J H Seashore
Journal:  J Pediatr Surg       Date:  1989-03       Impact factor: 2.545

9.  Totally implantable system for venous access in children with cystic fibrosis.

Authors:  J Cassey; W D Ford; L O'Brien; A J Martin
Journal:  Clin Pediatr (Phila)       Date:  1988-02       Impact factor: 1.168

10.  The pathology of fungal infection and colonization in patients with cystic fibrosis.

Authors:  V Bhargava; J F Tomashefski; R C Stern; C R Abramowsky
Journal:  Hum Pathol       Date:  1989-10       Impact factor: 3.466

View more
  10 in total

Review 1.  Persistent superior vena caval syndrome due to totally implantable venous access systems.

Authors:  P A Stockton; M J Ledson; M J Walshaw
Journal:  J R Soc Med       Date:  2001-11       Impact factor: 5.344

2.  Thrombolysis for indwelling catheter related thrombosis and superior vena cava obstruction in cystic fibrosis: a case series.

Authors:  T Hassan; S H Chotirmall; T B Low; M G Flynn; N G McElvaney; C Gunaratnam
Journal:  Ir J Med Sci       Date:  2010-06-19       Impact factor: 1.568

3.  Calcified catheter "cast" masquerading as a retained catheter fragment after removal of an implanted venous access device.

Authors:  M Shirin Sabbaghian; Rafael Rivera; Howard B Ginsburg; Evan P Nadler
Journal:  Pediatr Surg Int       Date:  2007-09       Impact factor: 1.827

4.  Risk factors for totally implantable venous access device-associated complications in cystic fibrosis.

Authors:  C McCarthy; O O'Carroll; M E O'Brien; T McEnery; A Franciosi; C Gunaratnam; N G McElvaney
Journal:  Ir J Med Sci       Date:  2017-08-15       Impact factor: 1.568

5.  Frequent AV node reentrant tachycardia induced by oversized port catheter.

Authors:  Stefan Andreas Lange; Jens Jung
Journal:  Support Care Cancer       Date:  2011-05-01       Impact factor: 3.603

Review 6.  Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis.

Authors:  Natalie E West; Traci M Kazmerski; Jennifer L Taylor-Cousar; Vin Tangpricha; Kelsie Pearson; Moira L Aitken; Raksha Jain
Journal:  Pediatr Pulmonol       Date:  2021-10-08

Review 7.  Increased vigilance needed for the detection of thrombotic complications of central venous access in adolescent cystic fibrosis patients.

Authors:  Nandini Kandamany; Basil Elnazir; Peter Greally
Journal:  Front Pediatr       Date:  2014-11-19       Impact factor: 3.418

8.  Incidence and Risk Factors for Totally Implantable Venous Access Device Infections in Pediatric Patients With Cancer: A Study of 25,954 Device-Days.

Authors:  Joon Kee Lee; Young Bae Choi
Journal:  J Korean Med Sci       Date:  2022-09-05       Impact factor: 5.354

9.  Results of Port-A-Cath Implantation: A Cross-Sectional Study about a Single Tertiary Cancer Center Experience.

Authors:  Fariba Jahangiri; Mahmoud Salek; Seyed Javad Nassiri; Fariborz Samadi; Mina Koohian Mohammadabadi
Journal:  Med J Islam Repub Iran       Date:  2022-06-15

10.  Complications of chemoport in children with cancer: Experience of 54,100 catheter days from a tertiary cancer center of Southern India.

Authors:  S Aparna; S Ramesh; L Appaji; Kavitha Srivatsa; Gowri Shankar; Vinay Jadhav; Narendra Babu
Journal:  South Asian J Cancer       Date:  2015 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.